TABLE 1. Characteristics of trials included in systematic review.

Author, year, country	Comparison	Exclusion criteria	HPV test useda	Cytology method	Outcome measured	Threshold for colposcopy	Size, NC/NHb
Ronco et al,16 2010, Italy (NTCCS trial) Total n = 94,370	Phase 1, 25-34 y old: cytology alone vs HPV plus cytology (passive response)	Pregnant, history of hysterectomy, treatment for CIN in past 5 y, age 25 y or younger or 60 y or older	hc2	Conventional and LBC	CIN2 or greater, CIN3 or greater, cancerc	Cyto: ASCUS or greater (7/9 centers) or LSIL or greater (2/9 centers) HPV: cytology positive as above or HPV test remains positive 12 months after initial testing	12,410 5808/6602
	Phase 1, 35-60 y old: cytology alone vs HPV plus cytology (active response)					Cyto: ASCUS or greater (7/9 centers) or LSIL (2/9 centers) HPV: positive HPV test or positive cytology, as above	33,364 16,658/16,706
	Phase 2, all ages: cytology alone vs HPV alone					Cyto: ASCUS or greater (7/9 centers) or LSIL or greater (2/9 centers) HPV: positive HPV test	49,196 24,535/24,661
Leinonen et al,20 2009, Finland (Finnish trial)	Cytology alone vs HPV plus cytology triage	Age 25 y or younger or 65 y or older	hc2	LBC	CIN1 or greater, CIN2 or greater, CIN3 or greater	Cyto: LSIL or greater HPV: positive HPV test followed by cytology LSIL or greater	71,337 35,500/35,837
Kitchener et al,18 2009, United Kingdom (ARTISTIC trial)	Cytology alone vs HPV plus cytology (passive response)	Age 20 y or younger or 60 y or older	hc2	Conventional	CIN2 or greater, CIN3 or greater	Cyto: HSIL or greater, 2 consecutive LSIL results, or 3 consecutive ASCUS results HPV: HPV test remains positive 12 months after initial testing or HSIL or greater	24,510 6124/18,386
Sankaranarayanan et al,17 2009, India (India trial)	Cytology alone vs HPV alone	Pregnant; history of cervical cancer, hysterectomy, or uterine prolapse; no history of marriage; age 30 y or younger or 59 y or older	hc2	Conventional	Cancer, cancer death	Cyto: ASCUS or greater HPV: positive HPV test	131,746 32,058/34,126
Rikjaart et al,13 2012, Netherlands (POBASCAM trial)	Cytology alone vs HPV plus cytology (passive response)	History of hysterectomy, CIN2 or greater or worse, or abnormal cytology in previous 2 y, age 29 y or younger or 56 y or older	GP5/GP6	Conventional	CIN2 or greater, CIN3 or greater	Cyto: HSIL or greater initially or repeated ASCUS results at 6 months HPV: HPV test remains positive at 6 or 18 months after initial testing or positive cytology, as above	40105 19999/20106
Naucler et al,19 2007, Sweden (SwedeScreen trial)	Cytology alone vs HPV plus cytology (passive response)	Age 32 y or younger or 38 y or older	GP5/GP6	Conventional	CIN2 or greater, CIN3 or greater	Cyto: ASCUS or greater (Stockholm) or HSIL or greater (all other cities) HPV: HPV test remains positive 12 months after initial testing or positive cytology, as above	12527 6270/6257

ARTISTIC, A Randomised Trial of HPV Testing in Primary Cervical Screening; ASCUS, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; Cyto, cytology; G, G serotype; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LBC, liquid based-cytology; LSIL, low-grade squamous intraepithelial lesion; NTCCS, New Technologies for Ceivical Cancer Screening; P, P genotype; POBASCAM, Population Based Screening Study Amsterdam.

^aThe hc2 (hybrid capture 2) was considered positive if 1 relative luciferase unit or greater;

^bN_C/N_H is the number of study subjects in the cytology group/number of study subjects in the HPV group;

^cIn most recent publication, CIN2+ signifies CIN2, CIN3, and AIS combined. CIN3+ signifies CIN3 and AIS combined.

Patanwala. HPV testing in cervical cancer screening. Am J Obstet Gynecol 2013.